In addition to αPD‐L1 and αPD1, αFc‐NPs could also be used for immobilizing other mAbs that targeting immunomodulatory molecules expressed by tumor cells and other immune cells (e.g., NK cells and macrophages), such as anti‐KLRG1 (killer‐cell lectin‐like receptor G1) antibody αKLRG1 with αPD‐L1 or anti‐CSF1R (colony stimulating factor 1 receptor) antibody (αCSF1R) with anti‐CD47 antibody (αCD47). This evidence concerns the gene CSF1R and neoplasm.